论文部分内容阅读
目的观察反应停联合VAD方案治疗难治性多发性骨髓瘤的临床疗效。方法将16例多发性骨髓瘤患者随机分为两组,治疗组9例采用反应停联合VAD方案,反应停起始剂量为100mg/d,每周增加50mg/d,最大剂量为200~400mg/d,持续12周以上;对照组7例采用单纯VAD方案,28d为1疗程,治疗3个疗程。结果治疗组总有效率为66.7%,对照组总有效率为42.9%,两组间疗效有显著性差异(P<0.05)。治疗组出现较对照组相对明显的不良反应有便秘、失眠,对症治疗后缓解。结论反应停联合VAD方案治疗多发性骨髓瘤疗效明显优于单用化疗组。
Objective To observe the clinical efficacy of combination therapy with VAD regimen in the treatment of refractory multiple myeloma. Methods Sixteen patients with multiple myeloma were randomly divided into two groups. In the treatment group, 9 cases were treated with VAD combined with VAD. The initial starting dose was 100 mg / d, and the weekly increase was 50 mg / d. The maximum dosage was 200-400 mg / d for more than 12 weeks; the control group of 7 patients with simple VAD program, 28d for a course of treatment, the treatment of 3 courses. Results The total effective rate was 66.7% in the treatment group and 42.9% in the control group, with significant difference between the two groups (P <0.05). The treatment group appeared more obvious than the control group of adverse reactions are constipation, insomnia, symptomatic relief after treatment. Conclusions The combination of VTA and VAD regimen in treating multiple myeloma is superior to chemotherapy alone.